51834-97-0

Usage

Uses

Used in Pharmaceutical Industry:
5-HYDROXY-2-METHOXYPYRIDINE is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications, including those targeting specific diseases or conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-HYDROXY-2-METHOXYPYRIDINE is used as a key building block for creating a wide range of organic molecules. Its reactivity and structural diversity make it a valuable component in the development of new chemicals with various applications, such as agrochemicals, dyes, and other specialty chemicals.
Used in Research and Development:
5-HYDROXY-2-METHOXYPYRIDINE is also utilized in research and development settings, where it can be employed to study the properties and reactivity of heterocyclic compounds. This knowledge can be applied to the design and synthesis of new molecules with specific functions or properties, contributing to the advancement of various scientific fields.

InChI:InChI=1/C6H7NO2/c1-9-6-3-2-5(8)4-7-6/h2-4,8H,1H3

Upstream product

• 58243-27-9 5-acetoxy-2-methoxy-pyridine 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 121-43-7 Trimethyl borate 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 1228447-95-7 5-(iso-propoxydimethylsilyl)-2-methoxypyridine 
• 163105-89-3 2-methoxy-pyridine-5-boronic acid 
• 13472-61-2 5-iodo-2-methoxypyridine 
• 445264-61-9 2-methoxy-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)pyridine 
• 1083329-15-0 5-(benzyloxy)-2-methoxypyridine 
• 624-28-2 2,5-dibromopyridine 
• 1628-89-3 2-methoxypyridine 

Downstream Products

• 5154-01-8 pyridine-2,5-diol 
• 431942-25-5 2-methoxy-5-(methoxymethoxy)pyridine 
• 867267-29-6 2-methoxy-5-(triisopropylsilanyloxy)pyridine 
• 867267-24-1 2,5-dimethoxypyridine 
• 431942-27-7 5-hydroxy-4-iodo-5-methoxypyridine 
• 431942-26-6 4-iodo-2-methoxy-5-(methoxymethoxy)pyridine 
• 431942-29-9 5-methoxy-2-phenylfuro[2,3-c]pyridine 
• 431942-37-9 5-hydroxy-2-methoxy-4-(2-phenylethynyl)pyridine 
• 431942-39-1 3-hydroxymethyl-5-methoxy-2-phenylfuro[2,3-c]pyridine 
• 431942-36-8 2-methoxy-5-methoxymethoxy-4-(2-phenylethynyl)pyridine 
• 431942-41-5 2-(5-methoxy-2-phenylfuro[2,3-c]pyridin-3-yl)acetonitrile 
• 431942-38-0 methyl 5-methoxy-2-phenylfuro[2,3-c]pyridine-3-carboxylate 
• 431942-40-4 5-methoxy-2-phenylfuro[2,3-c]pyridin-3-ylmethyl-4-toluenesulfonate 
• 228401-39-6 4-(5-(2-methoxy)pyridyl)oxy-1-nitrobenzene 

Relevant academic research and scientific papers

3-pyridinols and 5-pyrimidinols: Tailor-made for use in synergistic radical-trapping co-antioxidant systems

The incorporation of nitrogen atoms into the aromatic ring of phenolic compounds has enabled the development of some of the most potent radical-trapping antioxidants ever reported. These compounds, 3-pyridinols and 5-pyrimidinols, have stronger O-H bonds than equivalently substituted phenols, but possess similar reactivities toward autoxidation chain-carrying peroxyl radicals. These attributes suggest that 3-pyridinols and 5-pyrimidinols will be particularly effectiveco-antioxidants when used in combination with more common, but less reactive, phenolic antioxidants such as 2,6-di-tert-butyl-4- methylphenol (BHT), which we demonstrate herein. The antioxidants function in a synergistic manner to inhibit autoxidation; taking advantage of the higher reactivity of the 3-pyridinols/5-pyrimidinols to trap peroxyl radicals and using the less reactive phenols to regenerate them from their corresponding aryloxyl radicals. The present investigations were carried out in chlorobenzene and acetonitrile in order to provide some insight into the medium dependence of the synergism and the results, considered with some from our earlier work, prompt a revision of the H-bonding basicity value of acetonitrile to β 2H of 0.39. Overall, the thermodynamic and kinetic data presented here enable the design of co-antioxidant systems comprising lower loadings of the more expensive 3-pyridinol/5-pyrimidinol antioxidants and higher loadings of the less expensive phenolic antioxidants, but which are equally efficacious as the 3-pyridinol/5-pyrimidinol antioxidants alone at higher loadings.

Cu(I)/sucrose-catalyzed hydroxylation of arenes in water: The dual role of sucrose

A protocol for the hydroxylation of aryl halides catalyzed by copper(I) and sucrose in neat water has been developed. The dual role of sucrose, the reaction pathway, and the high selectivity for hydroxylation were investigated using a combination of experimental and theoretical techniques. This journal is

Trinuclear Mn2+/Zn2+based microporous coordination polymers as efficient catalysts foripso-hydroxylation of boronic acids

Two microporous coordination polymers based on hourglass trinuclear building units, [Mn3(bpdc)3(bpy)]·2DMF and [Zn3(bpdc)3(bpy)]·2DMF·4H2O (bpdc = 4,4′-biphenyl dicarboxylic acid, bpy = 4,4′-bipyridine), have been synthesized under solvothermal conditions employing DMF as the solvent. Each structure consists of two crystallographically distinct M2+(M1 and M2) centers that are connectedviacarboxylate bridges from six bpdc ligands, generating a trinuclear metal cluster, [M3(bpdc)3(bpy)]. Cluster representation of the structure resulted in an interpenetrated net of rarehextopological type. Catalytic activities of the CPs have been assessed for the oxidative hydroxylation of phenylboronic acids (PBAs) using aqueous hydrogen peroxide (H2O2). Various substituted aryl/hetero-arylboronic acids RB(OH)2[R = phenyl, 2,4-difluorophenyl, 4-aminophenyl, 2-thiopheneetc.] underwentipso-hydroxylation smoothly at room temperature to generate the corresponding phenols in excellent yields. The main advantages of this protocol are the aqueous medium reaction, heterogeneous catalytic system, and short reaction time with excellent yield.

OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to the oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. Formula (I):

Cellulose as recyclable organocatalyst for ipso-hydroxylation of arylboronic acids

Cellulose catalyzed oxidative hydroxylation of aryl and hetero-arylboronic acids to the corresponding phenols under metal and base free strategy has been demonstrated. The sustainable ipso-hydroxylation takes place using hydrogen peroxide as an oxidant in water under mild condition in shorter period of time. Interestingly, easy recovery and reusability of heterogeneous catalyst without significant loss in catalytic yield makes the protocol environmentally benign.

Room-Temperature Ionic Liquids (RTILs) as Green Media for Metal- and Base-Free ipso -Hydroxylation of Arylboronic Acids

The oxidative hydroxylation of arylboronic acids to the corresponding phenolic compounds under metal- and base-free aerobic conditions is successfully demonstrated on a greener media. Hydrogen peroxide, as an eco-friendly oxidant, is compatible with green mediates room-temperature ionic liquids (RTIL)s, providing hydroxylation products of arylboronic acids in an efficient manner. The RTIL support is particularly interesting for its reusability.

Size-tunable ZnO nanotapes as an efficient catalyst for oxidative chemoselective C–B bond cleavage of arylboronic acids

Herein, we report a simple but effective chemical approach for the synthesis of size-tunable ZnO nanotapes by precipitation method in the presence of phytochemicals present in the flower extract of Lantana camara plant. The electron microscopic study confirmed that the size of ZnO nanotapes can be systematically controlled by varying the concentration of either flower extract or metal ions and the flower extract played the key role in controlling the growth of ZnO nanotapes. The phase and crystalline analysis was carried out by X-ray diffraction method which indicated that ZnO nanostructures are highly crystalline in nature and are free from any impurities. The synthesized ZnO nanostructures exhibited interesting optical properties as investigated by UV–vis absorption and photoluminescence spectroscopy. Further the surface functionalities affect the optical properties of ZnO nanostructures which possess relatively strong UV emissions; a blue emission and a green emission. The synthesized ZnO nanostructures showed excellent catalytic properties in the ipso-hydroxylation of different aryl/ hetero-arylboronic acid to phenol in a relatively greener reaction conditions. These catalysts are highly stable and are re-usable upto six cycles of ipso-hydroxylation without losing its catalytic properties.

Recyclable CNT-chitosan nanohybrid film utilized in copper-catalyzed aerobic ipso-hydroxylation of arylboronic acids in aqueous media

A convenient heterogeneous catalytic system consisting of recyclable and reusable carbon nanotube-chitosan nanohybrid film and copper salt was developed for the aerobic ipso-hydroxylation of arylboronic acids. A variety of arylboronic acids bearing electron-withdrawing or electron-donating groups were smoothly transformed at room temperature in water to afford the corresponding phenols in high yields.

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.